Cogent Biosciences, Inc. COGT
Updated: 10 Sep 2026
No signal published yet
We already track Cogent Biosciences and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Cogent Biosciences, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Cogent Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On August 10, 2026, Cogent Biosciences reported its second quarter 2026 financial results with $792.3 million in cash, cash equivalents, and marketable securities. The company highlighted three New Drug Applications for bezuclastinib under FDA review, with target PDUFA decision dates in late 2026. Management expects its existing cash balance to fund operations into late 2028.
What Firelda Watch includes for Cogent Biosciences, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Cogent Biosciences, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Cogent Biosciences free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more